美通社

2024-10-21 09:03

Chang Gung Memorial Hospital Unveils Cellular Therapy: A Beacon of Hope for Cancer Treatment

Cellular Therapy Emerges as a Front-Runner in Medical Innovation

TAOYUAN, Oct. 21, 2024 /PRNewswire/ -- Cellular therapy, a revolutionary approach where cells are manipulated outside the body and then reintroduced to treat or prevent diseases, has been recognized in recent years as a highly promising treatment in the medical field. Chang Gung Memorial Hospital in Taiwan has been at the forefront of this innovation since 2018, when it established a Good Tissue Practice (GTP) laboratory with six cell processing labs adhering to international PICS/GMP cleanliness standards. The hospital actively supports clinical trials for various immune cells and regenerative medicine, with its Department of Laboratory Medicine certified by the College of American Pathologists (CAP) and responsible for issuing quality control reports for cell production processes.

Chang Gung Memorial Hospital utilizes synthetic cancer cell antigens to train patients' immune cells to recognize and fight cancer cells. After multiplying, these immune cells are reintroduced into the body to eliminate cancer cells, all while using chemotherapy and radiotherapy to improve treatment outcomes. (Photo courtesy of Chang Gung Memorial Hospital)
Chang Gung Memorial Hospital utilizes synthetic cancer cell antigens to train patients' immune cells to recognize and fight cancer cells. After multiplying, these immune cells are reintroduced into the body to eliminate cancer cells, all while using chemotherapy and radiotherapy to improve treatment outcomes. (Photo courtesy of Chang Gung Memorial Hospital)

Autologous Dendritic Cell-Cytokine Induced Killer Cell Immunotherapy (DC-CIK)

Dr. Wei-Chen Lee, Vice-Superintendent at Chang Gung Memorial Hospital, Linkou, a leading institution in liver transplantation in Taiwan, has been researching autologous dendritic cells (DC) for liver cancer treatment since 1998. His therapy has achieved remarkable results, with no tumor growth post-treatment and a disease control rate of 70-80%. His team is now advancing research on cancer vaccines, aiming to initiate treatment immediately post-surgery to prevent cancer recurrence.

Professor John Yu from the Institute of Stem Cell and Translational Cancer Research (ISCTCR) has developed a novel three-stage "apexNK" expansion technology for natural killer (NK) cells. Combined with a high-efficiency viral transduction method, this technology produces new CAR-NK cells, overcoming the limitations of traditional CAR therapies in treating solid tumors. Director Shuen-Iu Hung from the Cancer Vaccine and Immune Cell Therapy Core Laboratory has completed Phase I clinical trials targeting tumor neoantigens for solid cancer treatment, paving the way for future applications in metastatic and multidrug-resistant tumors.

CAR-T Cell Therapy: A Living Drug Revolutionizing Cancer Treatment

CAR-T cell therapy, or chimeric antigen receptor T-cell therapy, represents a groundbreaking immunotherapy that combines gene therapy and cellular therapy. Dubbed the "living drug," the treatment modifies the patient's immune T-cells genetically, enabling them to precisely target and eliminate specific cancer cells. These engineered and expanded T-cells are then reintroduced into the patient's body. The therapy has demonstrated remarkable success in treating acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL), earning accelerated approval from the U.S. Food and Drug Administration (FDA).

Huahua, a 13-year-old, and Baobao, an 8-year-old, both boys, serve as examples. Both were diagnosed with ALL and later developed extramedullary relapse, with Huahua experiencing bilateral testicular enlargement and Baobao showing enlargement of the right testicle, accompanied by an increase in minimal residual disease (MRD).

Faced with these challenging cases, Dr. Shih-Hsiang Chen, Deputy Director of the hospital's Pediatric Department, noted the limited effectiveness of traditional hematopoietic stem cell transplantation for extramedullary relapse. Local treatments such as orchidectomy or radiotherapy could also significantly impact the reproductive function of pediatric patients. After thorough discussions with the patients' families, the decision was made to proceed with CAR-T cell therapy. Following treatment, both patients experienced only mild fever and fatigue and were discharged after approximately two weeks. They continue to receive outpatient follow-up care.

Dr. Cheng-Hsun Chiu, also a Vice-Superintendent at the hospital, said that advancements in cancer treatment have transformed the landscape, evolving from traditional radiotherapy and chemotherapy to targeted therapy, bone marrow transplantation, and now, pioneering cellular therapies like DC-CIK and CAR-T. Looking ahead, the evolution of immune cell therapy promises to usher in more technological breakthroughs, offering patients a broader array of treatment choices and significantly enhancing both treatment efficacy and quality of life.

source: Chang Gung Memorial Hospital, Linkou

【你點睇?】美歐官員今周商俄烏戰爭問題,你認為俄烏戰爭是否正加快步向結束?► 立即投票

人氣文章
最近7天
1
港股 | 蕭猷華:內地AI發展迅速,阿里巴巴股價看俏
2
高息定存 | 一周高息合集,銀行高息搶存,富邦1個月4.88厘,華僑1年期3.6厘
3
英偉達 | DeepSeek衝擊AI晶片行業結構 英偉達暴跌仍未急抄底
4
高息定存 | 花旗3個月港元定存息加至4厘,信銀國際3.88厘
5
環球央行 | 歐洲央行宣布再次減息0.25厘,符合市場預期
6
一本萬利 | 2025年的五個「勿」(有片)
7
啟德體育園明天足球賽測試,4.4萬公僕參與涉逾400萬車馬費
8
高息定存 | 華僑銀行推新春港元定存優惠,88天或188天享3.68厘
9
電騙 | 黃俊碩:多管齊下,防治內地留學生受騙
10
易經看世界 | 乙巳蛇年趨吉五招:言行注意甚麼?應遠離甚麼人?(有片)
11
PapaHome淘寶家具實體店22日開幕,選址尖沙咀中港城,料創100個就業機會
12
洪灝專訪 | 淘寶衝擊巨大,港樓價未反映大周期拐點(有片)
13
專訪|洪灝:美股更大跌幅在前面,恐需習慣4%通脹(有片)
14
習近平應約與特朗普通電話,特:冀盡快與習見面
15
新世界 | 摩通:新世界若債務違約或打開行業「潘朵拉盒子」
16
專訪 | 關稅戰 | 香港物流協會副會長梁庭彰:美物流商停收包裹對跨境電商打擊重大
17
【FOCUS】螺絲殼裏做道場,DeepSeek致勝啟示
18
港股 | 午市前瞻 | iPhone SE難救中國市場 專家提醒比電已超買
19
大S | 台灣藝人徐熙媛因流感併發肺炎逝世,享年48歲
20
DeepSeek推出即上蘋果中國區榜首,能力直追OpenAI
21
高息定存 | 一周高息合集,部分銀行逆市加息,南商3個月加至3.8厘
22
收市短打 | 楊韻銳:港股升勢有成交配合 惟留意關鍵阻力位!
23
高息定存 | 一周高息合集,蛇年定存金蛇起舞,1個月定存高達8厘
24
港股 | 蕭猷華:春節假後,恒指逐步上望21000點
25
特朗普就職 | 特朗普上台後行動列表
26
馬斯克明拆特朗普台,指其星際之門計劃「假大空」
27
【FOCUS】侵侵呼籲全球「降息」,日銀祭18年最激進加息
28
高息定存 | 富邦一周港元定存高達9.88厘,一個月4.88厘
29
神州經脈 | 特朗普或與華討論關稅,人民幣大漲,滬指連升兩周
30
港股 | 蕭猷華:恒指本周目標20500點
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

【etnet 30周年】多重慶祝活動一浪接一浪,好禮連環賞!

【蛇年行大運 新年好賞「飾」】etnet賞太歲開運趨吉避凶神器

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

貨幣攻略

大國博弈

說說心理話

Watch Trends 2024

北上食買玩

Art Month 2024

理財秘笈

流感高峰期

山今養生智慧

輕鬆護老